At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 550 enrolled
Drug / intervention
rhTNK-tPA +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Intravenous rhTNK-tPA Bridging With Endovascular Treatment Versus Endovascular Treatment Alone For Stroke Patient With Large Vessel Occlusion: A Multicenter, Randomized Controlled Trial
In Brief
A Phase 3 clinical trial evaluating rhTNK-tPA and Endovascular treatment for Stroke, Acute and Stroke, Ischemic. Completed, enrolled 550 participants across 6 sites.
Detailed Summary
The purpose of this trial is to investigate whether intravenous rhTNK-tPA prior to endovascular treatment can improve 90-day functional outcome of stroke patients with large vessel occlusion who are thrombolysis-eligible within 4.5 hours of symptom onset.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStroke, Acute, Stroke, Ischemic
CountriesChina
CollaboratorsCSPC RECOMGEN PHARMACEUTICAL (GUANGZHOU) CO.,LTD
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedFeb 2021
Enrollment StartMay 2022
Primary CompletionDec 2024
Study CompletionFeb 2025
TodayJul 2026
First PostedFeb 2, 2021
Enrollment StartMay 9, 2022
Primary CompletionDec 16, 2024
Study CompletionFeb 7, 2025
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 5.4 years ago
Interventions
rhTNK-tPAdrug
intravenous thrombolysis with rhTNK-tPA followed by endovascular treatment
Endovascular treatmentother
endovascular treatment